GlaxoSmithKline | GSK - Equity Capital And Reserves


GlaxoSmithKline reported GBP17.64B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Alcon AG USD 22.13B 99M Mar/2026
Almirall EUR 1.53B 43.26M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
argenx SE USD 8.42B 1.09B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Bayer EUR 28.85B 2.9B Mar/2026
Biogen USD 18.85B 196.3M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Fresenius EUR 19.7B 766M Jun/2026
Fresenius Medical Care EUR 14.2B 13.95B Mar/2026
Genmab DKK 5.96B 275M Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
GRIFOLS EUR 7.98B 2.52B Jun/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Lakefront Biotherapeutics EUR 3.25B 17.5M Mar/2026
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 29.74B 1.15B Mar/2026
Merck USD 41.93B 3.94B Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Novo Nordisk DKK 221.28B 18.21B Jun/2026
Orion EUR 1.27B 146.5M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Philips EUR 11.48B 84M Jun/2026
Recordati EUR 2.13B 70.34M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Smith & Nephew USD 5.18B 356M Jun/2026
UCB EUR 10.87B 1.18B Dec/2025